mechanism mek inhibition determines efficacy mutant kras versus braf-driven cancers 
kras braf activating mutations drive tumorigenesis constitutive activation mapk pathway tumours represent area high unmet medical need multiple allosteric mek inhibitors inhibit mapk signalling genotypes tested clinical trials impressive single-agent activity braf-mutant melanoma observed however efficacy far less robust kras-mutant disease show owing distinct mechanisms regulating mek activation kras-versus braf-driven tumours different mechanisms inhibition required optimal antitumour activity genotype structural functional analysis illustrates mek inhibitors superior efficacy kras-driven tumours gdc g- former currently phase clinical trials form strong hydrogen-bond interaction s212 mek critical blocking mek feedback phosphorylation wild-type raf conversely potent inhibition active phosphorylated mek required strong inhibition mapk pathway braf-mutant tumours resulting superior efficacy genotype gdc also known cobimetinib mek inhibitor currently phase iii clinical trials study highlights differences activation state mek kras-mutant tumours versus braf-mutant tumours can exploited design inhibitors uniquely target distinct activation states mek inhibitors currently evaluated clinical trials determine whether improvements therapeutic index within kras versus braf preclinical models translate improved clinical responses patients 
